Three Different Doses of Neostigmine on the Reversal of Cisatracurium-induced Moderate Neuromuscular Blockade
Neuromuscular Blockade, Neuromuscular Blockade, Residual
About this trial
This is an interventional treatment trial for Neuromuscular Blockade
Eligibility Criteria
Inclusion Criteria:
- Patients physical status according to the American Society of Anesthesiologists I and II
- submitted to nose or ear surgeries under general anesthesia
Exclusion Criteria:
- Refusal to participate in the study
- Presence of kidney, liver or neuromuscular disease
- Contraindication to the use of any of the drugs used in the study
- Body mass index (BMI) ≥ 30.
Sites / Locations
- Santa Lucina Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Group I-30
Group I-50
Group I-70
Group V-30
Group V-50
Group V-70
Inhalational anesthesia and reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
Inhalational anesthesia and reversal with neostigmine 50 mcg/kg and atropine 25 mcg/kg
Inhalational anesthesia and reversal with neostigmine 70 mcg/kg and atropine 35 mcg/kg
Intravenous anesthesia and reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
Intravenous anesthesia and reversal with neostigmine 50 mcg/kg and atropine 25 mcg/kg
Intravenous anesthesia and reversal with neostigmine 70 mcg/kg and atropine 35 mcg/kg